Navigation Links
FDA Warns Users About Faulty Components in 14 External Defibrillator Models
Date:4/27/2010

Users should seek alternatives, if possible

SILVER SPRING, Md., April 27 /PRNewswire-USNewswire/ -- About 280,000 external defibrillators used worldwide in health care facilities, public places, or in the home may malfunction during attempts to rescue people in sudden cardiac arrest, the U.S. Food and Drug Administration warned today.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

Sudden cardiac arrest is a condition in which the heart suddenly and unexpectedly stops beating. When this happens, blood stops flowing to the brain and other vital organs, leading to death if not treated within minutes.

External defibrillators can send an electric shock to the heart to try to restore normal heart rhythm when sudden cardiac arrest occurs.

Faulty components in defibrillators manufactured by Cardiac Science Corp. of Bothell, Wash., may cause the devices to fail to properly deliver a shock. In addition to failure to deliver needed shocks, other problems with the affected models may include interruption of electrocardiography (ECG) analysis, failure to recognize electrode pads, and interference or background noise that makes the device unable to accurately analyze heart rhythm.

The 14 models, which include automated and semi-automated devices, are:

  • Powerheart models 9300A, 9300C, 9300D, 9300E, 9300P, 9390A and 9390E
  • CardioVive models 92531, 92532 and 92533
  • Nihon Kohden models 9200G and 9231 and
  • GE Responder models 2019198 and 2023440.

The FDA recommends that hospitals, nursing homes and other high-risk settings obtain alternative external defibrillators and arrange for the repair or replacement of the affected defibrillators.

For all other users, including those who use the device at home or as part of public access programs, the FDA recommends using alternative external defibrillators if they are available, and arranging for the repair or replacement of the affected models.

If alternative external defibrillators are not immediately available, then FDA recommends continuing to use the affected devices if needed, because they may still deliver necessary therapy.  The potential benefits of using the available external defibrillators outweigh the risk of not using any of the affected external defibrillators or the risk of device failure.

"The FDA is issuing this notice so that users can take the proper steps necessary to assure they have access to safe and effective defibrillators," said Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health.

Cardiac Science recalled its Powerheart and CardioVive models, manufactured between August 2003 and August 2009, on Nov. 13, 2009. But the FDA has since learned that additional Cardiac Science models, two marketed under the Nihon Kohden name, and two marketed by GE Healthcare as GE Responder have similar problems.

Cardiac Science issued a software update for two of its Powerheart defibrillators in February 2010 and plans to issue similar software updates for other affected devices. However, FDA's review of the updated software indicates that the software detects some, but not all, identified defects.

Nihon Kohden is based in Tokyo, Japan. GE Healthcare is located in Britain.

For more information

Defective Cardiac Science Corporation Powerheart, CardioVive, Nihon Kohden, and GE Responder External Defibrillators:  Updated April 27, 2010

http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm191426.htm

Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes
2. Physicians Foundation Warns of Potential Impact From New Medicare Cuts Effective Today
3. FDA Warns Consumers about Counterfeit Alli
4. Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public
5. Orkin Warns of Four Pests to Avoid this Fourth of July
6. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
7. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Lebanon County Dairy
8. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Chester County Dairy
9. The Results are in: Users of BodyMedias Wearable Body-Monitoring Technology Lose 3 Times More Weight
10. Elekta VMAT Radiation Therapy Rapidly Gaining Users Worldwide as Technique Evolves
11. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research and ... Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" ... ... 2021 from its current market size in 2016. The Untapped Proton Therapy ... than 1 Billion USD in 2016. Proton Therapy plays ...
(Date:3/29/2017)...  Zynex (OTCQB: ZYXI), an innovative medical technology company specializing ... for pain management, stroke rehabilitation, cardiac monitoring and neurological ... 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 a.m. ... expects to file its 2016 full year financial results ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 30, 2017 , ... Grass pollen is the main cause of hay ... the stuff. The season for grass pollen runs from May to July each year; with ... fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and ... two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, ...
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
Breaking Medicine News(10 mins):